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Abstract
Background: This study aimed to develop a simultaneous determination method for tramadol and its
desmethylates in human plasma using isocratic liquid chromatography coupled to tandem mass spectrometry and
to validate it for pharmacokinetic evaluation in patients with cancer pain or non-cancer pain.
Methods: The pretreatments for human plasma involved protein precipitation using acetonitrile and methanol
under basic conditions. Tramadol, O-desmethylate, N-desmethylate, and N,O-didesmethylate were separated on an
octadecylsilyl column filled with 3-μm particles using isocratic mixture of methanol and 0.15 % formic acid in water
(35:65, v/v). The mass spectrometer was run in positive ion multiple reaction monitoring mode. This method was
applied to the determination of plasma samples in patients treated with oral tramadol.
Results: The chromatographic total run time was 10 min. The calibration curves in human plasma of
tramadol, O-desmethylate, N-desmethylate, and N,O-didesmethylate were linear over the concentration ranges
of 12.5–1600, 2.5–320, 2.5–320, and 2.5–320 ng/mL, respectively. The lower limits of quantitation of tramadol
and its desmethylates in human plasma were 12.5 and 2.5 ng/mL. Their extraction recoveries were 85.5–106.
3 %. The intra-day and inter-day precisions and accuracies were 1.6–10.2 % and 89.2–106.2 % for all analytes.
The plasma concentration ranges of tramadol, O-desmethylate, N-desmethylate, and N,O-didesmethylate were 18.2–564,
11.8–137, 4.9–250, and 6.1–147 ng/mL in cancer patients, and 32.8–670, 7.0–84.8, 5.1–317, and 6.7–85.2 ng/mL,
respectively, in non-cancer patients.
Conclusions: The present method with acceptable analytical performance can be helpful for evaluating the
pharmacokinetics of oral tramadol, including the determination of its desmethylates, for patients with cancer pain or non-
cancer pain in clinical settings.
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Background
Tramadol, a centrally acting analgesic agent, is com-
monly used for the treatment of cancer pain and non-
cancer pain as an alternative to opioid analgesics [1].
Tramadol dually acts as an opioid μ1 receptor agonist
and a monoamine reuptake inhibitor [2, 3]. Based on
these actions, tramadol is effective for complicated pain
associated with neuropathic disorders. The common ad-
verse effects of tramadol are somnolence, nausea, and
vomiting. Serious adverse effects involving seizures and
serotonin syndrome potentially also occur with thera-
peutic doses of tramadol [4]. The incidence of these ad-
verse effects can lead to drug withdrawal or poor pain
control. The analgesic and adverse effects of tramadol
show a large interindividual variability in patients with
cancer pain or non-cancer pain [5].
Tramadol is rapidly absorbed from the intestine after
oral administration and its oral bioavailability is 65–70 %
due to first-pass metabolism [6]. Tramadol is metabolized
to O-desmethyltramadol (ODT) primarily by cytochrome
P450 (CYP) 2D6, and N-desmethyltramadol (NDT) by
CYP2B6 and CYP3A4. ODTand NDTare further metabo-
lized to N,O-didesmethyltramadol (NODT) by CYPs [7].
ODT has a 700-fold higher affinity towards opioid μ1 re-
ceptors than tramadol and is the main contributor to the
analgesic efficacy of tramadol pharmaceuticals. NDT and
NODT have a weak affinity for opioid μ1 receptors and
weak inhibition of monoamine reuptake [8]. The pharma-
cokinetics of tramadol and its desmethylates show a large
interindividual variability in humans [9]. In addition, the
relationships between the plasma concentrations of trama-
dol and its desmethylates and clinical effects remain to be
clarified in clinical settings.
Tramadol and its desmethylates in human plasma have
been determined using several chromatographic tech-
niques such as liquid chromatography (LC) coupled to
ultraviolet or fluorescence detection, and LC coupled to
tandem mass spectrometry (MS/MS) [10–12]. In general,
ultraviolet detection from biological specimens such as
plasma and urine is not suitable because of low sensitivity
and selectivity [13, 14]. The LC separation of tramadol,
ODT, NDT, and NODT using ultraviolet or fluorescence
detection requires surfactants such as triethylamine and
sodium dodecyl sulfate [15, 16]. These surfactants cause
the ionic suppression of analytes in MS/MS analysis. MS/
MS detection of tramadol and its desmethylates possesses
high sensitivity and selectivity. However, distinguishing
between ODT and NDT in MS/MS analysis requires LC
separation due to similar molecular mass and fragmenta-
tion patterns. LC-MS/MS has a limit with regards to the
selection of the mobile phase because of poor ionization
of the desmethylates. To date, few practical methods using
simultaneous LC-MS/MS are available for the determin-
ation of tramadol and its desmethylates in human plasma.
The potential pharmacokinetic differences between
cancer and non-cancer patients were observed in recent
reports [17, 18]. However, few validated method is avail-
able for the determination of tramadol and its desmethy-
lates in human plasma in patients with non-cancer pain.
The development of effective and validated chromato-
graphic methodologies for the determination of tramadol
and its desmethylates in human specimens is needed for
clinical use. This study aimed to develop a simultaneous
determination method for tramadol and its desmethy-
lates in human plasma using an isocratic LC-MS/MS.
The method was validated in terms of pharmacokinetic




Tramadol, ODT, NDT, NODT, and tramadol-d6 as an in-
ternal standard (IS) were obtained from Toronto Research
Chemicals Inc. (Toronto, Ontario, Canada). HPLC-grade
methanol and 28 % ammonia solution were purchased
from Wako Pure Chemicals (Osaka, Japan). All other re-
agents were of analytical grade and commercially available.
Solutions
Stock solutions of tramadol (100 μg/mL), ODT
(50 μg/mL), NDT (50 μg/mL), NODT (20 μg/mL), and
IS (20 μg/mL) were prepared in methanol. Standard
solutions of tramadol, ODT, NDT, and NODT were
obtained by the dilution of stock solution with metha-
nol. Calibration standards were prepared in drug-free
pooled plasma (Kohjin-Bio Co., Ltd, Sakado, Japan).
The final concentrations of tramadol were 12.5, 25, 50,
100, 200, 400, 800, and 1600 ng/mL, while those of
ODT, NDT, and NODT were 2.5, 5, 10, 20, 40, 80,
160, and 320 ng/mL. Quality control (QC) samples
were spiked to tramadol concentrations of 12.5, 50,
200, and 800 ng/mL and ODT, NDT, and NODT con-
centrations of 2.5, 10, 40, and 160 ng/mL in drug-free
plasma.
Sample pretreatment
Blood specimens were collected into EDTA dipotassium
salt (2 K) tubes. Plasma was obtained by centrifugation
of the blood at 1670 × g at 4 °C for 10 min and then
stored at −80 °C until sample pretreatment. To 100 μL
aliquots of plasma, 600 μL of acetonitrile, 100 μL of IS
solution (50 ng/mL), and 20 μL of 28 % ammonia solu-
tion were added into a microtube. After 30 min on a
vortex mixer, the mixtures were stored at −35 °C for
30 min and ultrasonicated for 30 min. The mixtures
were centrifuged at 17,900 × g at 4 °C for 20 min, and
then 750 μL of the supernatant was evaporated to dry-
ness by rotary vacuum evaporation without heating. The
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residues were reconstituted with 150 μL of mixture con-
taining methanol and 0.15 % formic acid in water (1:1,
v/v). After 30 min on a vortex mixer, the mixtures were
ultrasonicated for 30 min. The mixtures were centri-
fuged at 17,900 × g at 4 °C for 20 min. The supernatants
were filtrated with a Millex-LH syringe filter (0.45 μm,
4 mm, Merck Millipore Ltd., Billerica, MA, USA) before
injection into the LC.
Chromatographic conditions
Tramadol, ODT, NDT, NODT, and IS in human
plasma were separated using a validated LC system
(UFLCXR, Shimadzu Corporation, Kyoto, Japan). The
LC system consisted of a CBM-20A system controller,
DGU-20A5R degasser, LC-20ADXR pump, SIL-20ACXR
autoinjector, and CTO-20AC column oven. Separation
was performed using a 3-μm particle ODS column
(TSKgel ODS-100 V, 150 × 2.0 mm I.D., Tosoh, Tokyo,
Japan) with a guard column (TSKguardgel ODS-100 V,
3 μm particle size, 10 × 2.0 mm I.D., Tosoh). The mo-
bile phase consisted of methanol and 0.15 % formic
acid in water (35:65, v/v). The flow rate was 0.2 mL/
min and the column temperature was set at 40 °C, and
the autoinjector was set at 4 °C. The injection volume
was 10 μL.
Mass spectrometric conditions
The column effluent was monitored using a triple quadru-
pole mass spectrometer (3200 QTRAP®, AB Sciex, Foster
City, CA, USA) equipped with an electrospray probe in
positive ionization mode. It was controlled by Analyst soft-
ware Version 1.6.1 (AB Sciex). The ion transitions were
monitored using a dwell time of 200 milliseconds for each
compound: tramadol, 264.2/58.2; ODT, 250.2/58.2; NDT,
250.2/232.2; NODT, 236.1/218.4; and IS, 270.2/64.1 (Fig. 1).
Samples were introduced to the interface through a turbo
ion spray with the temperature set at 600 °C. A high posi-
tive voltage of 5.5 kV was applied to the ion spray. Collision
gas, curtain gas, ion source gas 1, and ion source gas 2 were
set at 5 psi, 30 psi, 60 psi, and 60 psi, respectively. Collision
energy for tramadol, ODT, NDT, NODT, and tramadol-d6
were −31, −31, −13, −13, and −35 V, respectively.
Method validation
Selectivity of the method was evaluated by analyzing six





Fig. 1 Mass spectra of tramadol (a), O-desmethylate (b), N-desmethylate (c), and N,O-didesmethylate (d). A mass-to-charge (m/z) of 264.2/58.2
was monitored for tramadol, 250.2/58.2 for O-desmethylate, 250.2/232.2 for N-desmethylate, and 236.1/218.4 for N,O-didesmethylate
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were obtained by plotting the measured peak area ratios
of tramadol, ODT, NDT, and NODT to IS. The linearities
of tramadol, ODT, NDT, and NODT were observed at
concentration ranges of 12.5–1600, 2.5–320, 2.5–320, and
2.5–320 ng/mL, respectively. Accuracy and precision were
calculated for four QC samples in plasma. The lower limit
of quantification (LLOQ) was defined as the concentration
at which the relative standard deviation (RSD) does not
exceed 20 %. Accuracies were determined by evaluating
the analytical recovery of known amounts of plasma speci-
mens. The intra-assay and inter-assay precisions were
expressed as the RSD. Pretreatment recovery and matrix
effect were assessed by three and five replicates of spiked
human plasma at 25–400 and 5–80 ng/mL of tramadol
and its desmethylates, respectively. The stabilities of ana-
lytes in plasma were evaluated by comparing peak areas
after 24 h of storage at 4 °C and room temperature with
initial peak area. Long-term stabilities in plasma at −80 °C
were determined after 1 month. Analytical stabilities in in-
jection solutions were evaluated by comparing peak areas
after 24 h of storage at 4 °C with initial peak area.
Patients and pharmacokinetic evaluation
A total of 30 Japanese patients, 15 with cancer pain and
15 with non-cancer pain, treated with oral tramadol at
Hamamatsu University Hospital were enrolled (Table 1).
The patients received tramadol oral dispersing tablets
(Tramal®, Nippon Shinyaku Co., Ltd., Kyoto) or tramadol
combination tablets (Tramcet combination Tablets®,
Janssen Pharmaceutical K.K., Tokyo) four times a day for
cancer pain and three times a day for non-cancer pain.
The median daily dose was 100 mg for cancer pain and
112.5 mg for non-cancer pain. No patient was co-treated
with potent enzyme modifiers such as an azole antifun-
gal agent or rifampicin. Two mL blood samples were
collected at 8 h post-dose (before breakfast) on the 4th
day after initiation of therapy or later. The plasma con-
centrations of tramadol and its desmethylates were eval-
uated as the trough plasma concentration and the
trough adjusted values. The metabolism of tramadol was
estimated using the ratio of the plasma concentration of
the desmethylates to tramadol as the metabolic ratio.
Results
Separation and selectivity
Figure 2 shows the LC-MS/MS chromatograms of trama-
dol, ODT, NDT, NODT, and IS in human plasma. No peaks
interfering with tramadol, ODT, NDT, NODT, or IS in six
independent drug-free plasma specimens in cancer and
non-cancer patients were observed (Fig. 2a). Tramadol,
ODT, NDT, NODT, and IS were eluted at 6.1, 3.4, 7.4, 3.9,
and 6.0 min, respectively, with a total run time of 10 min
(Fig. 2b). In addition, no peaks interfering with detection in
tramadol non-treated patients with cancer pain or non-
cancer pain were observed (Fig. 2c and d).
Calibration curve, sensitivity, recovery, and matrix effect
The calibration curves of tramadol, ODT, NDT, and NODT
in human plasma were linear over the concentration ranges
of 12.5–1600, 2.5–320, 2.5–320, and 2.5–320 ng/mL,
respectively. Their correlation coefficients were greater than
0.999. The LLOQ of tramadol, ODT, NDT, and NODT in
human plasma were 12.5, 2.5, 2.5, and 2.5 ng/mL, respect-
ively (n = 6). The pretreatment recoveries including
deproteinization of tramadol, ODT, NDT, and NODT were
mean ± standard deviation (SD), 86.0 ± 3.4 %, 85.5 ± 1.8 %,
106.3 ± 2.9 %, and 93.9 ± 0.8 %, respectively. The analytes
and IS did not exhibit any matrix effects in human plasma
(mean ± SD, 88.3 ± 4.1 % for tramadol, 89.9 ± 5.6 % for
ODT, 105.1 ± 2.7 % for NDT, 98.8 ± 6.4 % for NODT, and
91.7 ± 4.9 % for IS, n = 5).
Assay accuracy and precision in human plasma
Table 2 shows the intra- and inter-assay accuracies and
precisions in human plasma. The intra-assay and inter-
assay accuracies of tramadol, ODT, NDT, and NODT
were 102.0–106.2 % and 95.1–103.4 %, 93.4–102.0 %
and 94.9–100.8 %, 89.2–105.2 % and 92.7–101.6 %, and
92.5–102.5 % and 97.5–99.8 %, respectively. The intra-
assay and inter-assay precisions of tramadol, ODT, NDT,
and NODT were 1.6–8.2 % and 4.6–6.3 %, 3.6–4.8 %
and 2.7–5.1 %, 3.4–7.9 % and 3.2–6.3 %, and 6.2–8.7 %
and 4.2–10.2 %, respectively.
Stability tests
The stock solutions of tramadol, ODT, NDT, NODT,
and IS were stable at 4 °C (% of initial value, 88.3–
99.1 %) for up to 3 months. Tramadol, ODT, NDT, and
NODT in plasma specimens were stable at room
temperature (% of initial value, 88.1–113.3 %) for up to
24 h. Tramadol, ODT, NDT, and NODT in plasma
specimens were stable at −80 °C (% of initial value,
89.9–111.8 %) for up to 1 month. Tramadol, ODT,
NDT, NODT, and IS in injection solutions were stable
at 4 °C (% of initial value, 92.6–104.6 %) for up to 24 h.
Plasma concentrations of tramadol and its desmethylates
Figure 3 shows the plasma concentrations of tramadol
and its desmethylates in cancer pain and non-cancer pain
patients treated with oral tramadol. The plasma concen-
trations of tramadol, ODT, NDT, and NODT in patients
with cancer pain ranged from 18.2 to 564, 11.8 to 137, 4.9
to 250, and 6.1 to 147 ng/mL, respectively. In patients
with non-cancer pain, the plasma concentrations of tram-
adol, ODT, NDT, and NODT ranged from 32.8 to 670, 7.0
to 84.8, 5.1 to 317, and 6.7 to 85.2 ng/mL, respectively.
The plasma concentration ranges of tramadol and its
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desmethylates were measurable within their calibration
curves in cancer and non-cancer patients.
Variations in plasma exposure and metabolic ratio
The median and interquartile range (IQR) of dose-
adjusted plasma concentrations for tramadol, ODT,
NDT, and NODT were 73.6 and 33.4–88.2, 14.8 and
9.1–34.0, 14.0 and 7.9–26.1, and 12.3 and 7.5–18.8 ng/
mL per mg/kg in patients with cancer pain, respectively.
In patients with non-cancer pain, the median dose-
adjusted plasma concentrations of tramadol, ODT, NDT,
and NODT were 122 (IQR, 96.2–180), 19.2 (10.3–20.7),
29.1 (10.6–78.5), and 10.4 (5.2–20.7) ng/mL per mg/kg,
respectively. The median metabolic ratios to ODT, NDT,
and NODT were 0.30 (IQR, 0.22–0.36), 0.25 (0.15–0.43),
and 0.23 (0.12–0.32) in patients with cancer pain, re-
spectively. In patients with non-cancer pain, the median
metabolic ratios to ODT, NDT, and NODT were 0.15
(IQR, 0.09–0.22), 0.19 (0.13–0.51), and 0.09 (0.06–0.19),
respectively.
Discussion
Development of effective and practical chromatographic
methodologies for the determination of tramadol and its
desmethylates in human specimens is needed for clinical
use. This study developed a simultaneous determination
Fig. 2 MS/MS chromatograms of human drug-free plasma (a), human drug-free plasma spiked with 200 ng/mL tramadol, 40 ng/mL O-desmethylate,
40 ng/mL N-desmethylate, and 40 ng/mL N,O-didesmethylate, (b) a plasma specimen at 8 h after evening dosing in cancer pain (c) and non-cancer
pain (d) patients treated with oral tramadol. (1) Tramadol, (2) O-desmethylate, (3) N-desmethylate, (4) N,O-didesmethylate, and (5) tramadol-d6 as
internal standard
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method for tramadol and its desmethylates in human
plasma using an isocratic LC-MS/MS and to evaluate its
clinical suitability in patients with cancer pain and non-
cancer pain. The chromatographic run time was 10 min.
The calibration curves of tramadol and its desmethylates
in human plasma were linear over the concentration
ranges of 12.5–1600 and 2.5–320 ng/mL, respectively.
The accuracy and precision data obtained with this
method met the standards of an international guideline
[19]. The plasma concentration ranges of tramadol and
its desmethylates were measurable within their calibra-
tion curves in cancer and non-cancer patients. The
present method with acceptable analytical performance
can be helpful for evaluating the pharmacokinetics of
tramadol in patients with cancer pain or non-cancer
pain in clinical settings.
The pretreatments for human plasma involved protein
precipitation using acetonitrile and methanol under
basic conditions. The pretreatment recoveries of trama-
dol and its desmethylates in the present method were
more than 85 %. Ardakani et al. reported on liquid-
liquid extraction from plasma specimens using ethyl
acetate under basic conditions [11]. The pretreatment
recoveries of tramadol and ODT ranged from 74.7 to
80.8 % and 76.9 to 87.3 %, respectively. Liquid-liquid ex-
traction using tert-butylmethyl ether and ethyl acetate
with ammonium solution was also described [20]. In this
pretreatment, the recoveries of tramadol and ODT
Table 2 Intra- and inter-assay precisions and accuracies of tramadol and its desmethylates in human plasma
Sample analytes Theoretical value
(ng/mL)
Intra-assay (n = 6) Inter-assay (n = 6)
Mean ± SD (ng/mL) Accuracy (%) RSD (%) Mean ± SD (ng/mL) Accuracy (%) RSD (%)
Tramadol 12.5 13.3 ± 0.71 106.2 4.8 12.6 ± 0.87 101.2 6.3
50 51.7 ± 4.69 103.3 8.2 51.8 ± 3.49 103.4 6.0
200 203.7 ± 12.9 102.0 6.0 204.2 ± 10.5 102.2 4.8
O-desmethylate 800 819.8 ± 13.1 102.5 1.6 761.3 ± 39.3 95.1 4.6
2.5 2.49 ± 0.14 99.5 4.8 2.52 ± 0.08 100.8 2.7
10 9.67 ± 0.38 96.7 3.6 9.90 ± 0.39 99.0 3.6
40 37.4 ± 1.82 93.4 4.5 38.0 ± 2.14 94.9 5.1
N-desmethylate 160 162.8 ± 7.52 102.0 4.4 159.2 ± 6.46 99.7 3.8
2.5 2.23 ± 0.20 89.2 7.9 2.41 ± 0.09 96.5 3.2
10 10.5 ± 0.40 105.2 3.4 10.2 ± 0.70 101.6 6.3
40 37.3 ± 2.66 93.3 6.5 37.1 ± 1.60 92.7 4.0
N,O-desmethylate 160 157.0 ± 8.83 98.2 5.2 155.0 ± 8.12 96.8 4.8
2.5 2.32 ± 0.22 92.7 8.7 2.49 ± 0.17 99.8 6.2
10 9.2 ± 0.77 92.5 7.6 9.77 ± 1.09 97.7 10.2
40 41.0 ± 3.09 102.2 6.9 39.5 ± 2.71 98.8 6.3
160 164.2 ± 11.1 102.5 6.2 155.8 ± 6.79 97.5 4.2
SD standard deviation, and RSD relative standard deviation
Table 1 Patient characteristics
Cancer Non-cancer
Gender, male/female 12/3 8/7
Age (years) 69 (66–73) 68 (67–77)
Body weight (kg) 44.9 (41.8–56.4) 55.9 (48.9–62.4)
Total protein (g/dL) 6.3 (6.0–6.5) 6.9 (6.0–7.5)
Serum albumin (g/dL) 3.2 (3.0–3.7) 3.1 (3.0–3.8)
Serum creatinine (mg/dL) 0.81 (0.65–0.93) 0.79 (0.59–0.95)
Blood urea nitrogen (mg/dL) 16.0 (13.4–19.2) 15.4 (14.1–20.1)
Total bilirubin (mg/dL) 0.4 (0.3–0.5) 0.5 (0.4–0.7)
Aspartate aminotransferase (IU/L) 18 (16–28) 28 (22–46)
Alanine aminotransferase (IU/L) 19 (13–35) 25 (17–41)
Data are expressed as median and interquartile range in parentheses
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ranged from 70 to 86 %. Sample pretreatment under
basic conditions achieves high and stable pretreatment
recoveries because the acid dissociation constant (pKa)
of tramadol is 9.4. The present simple pretreatment
without liquid-liquid extraction employed ammonium
solution as a basic volatile reagent. The ammonium so-
lution did not affect the MS/MS analysis owing to the
evaporation of precipitate solution. These data indicate
that the deproteinization including ammonia solution is
suitable for the clean-up of tramadol and its desmethy-
lates in human plasma.
The LLOQs of the present method for tramadol, ODT,
NDT, and NODT were 12.5, 2.5, 2.5, and 2.5 ng/mL in
human plasma, respectively. The LLOQ was defined as
the concentration at which the RSD does not exceed
20 %. A validated method with sensitivity of 10 ng/mL
for tramadol and 2.5 ng/mL for desmethylates is needed
for evaluating the pharmacokinetics of oral tramadol in
clinical settings. Ardakani et al. reported the simultan-
eous determination of tramadol, ODT, NDT, and NODT
using HPLC-fluorescence detection [11]. The sensitivity
of our present MS/MS method was similar to that of
their HPLC-fluorescence method. Patel et al. described
an LC-MS/MS method with LLOQs of 1 ng/mL for
tramadol and 0.5 ng/mL for ODT [12]. Figure 2b shows
the MS/MS chromatograms of human drug-free plasma
spiked with 200 ng/mL tramadol, 40 ng/mL ODT,
40 ng/mL NDT, and 40 ng/mL NODT. Since NDT and
NODT have less ionized property than ODT in mobile
phase, our method is optimized for the MS/MS detec-
tion of NDT and NODT. Meyer et al. developed the LC-
MS/MS method for the determination of plasma trama-
dol and ODT with LLOQ of 1 ng/mL [21]. This method
has no analytical conditions for the determination of
plasma NDT and NODT. The present LLOQs are suffi-
cient to determine the plasma concentrations of trama-
dol and its desmethylates in clinical settings. Our
method can determine the plasma tramadol and its des-
methylates in patients treated with oral tramadol.
The run time for the LC separation was 10 min in this
study. Our method determined tramadol and its des-
methylates isocratically using a conventional ODS column
with 3-μm particle size. The mobile phase consisted of
methanol and 0.15 % formic acid without nonvolatile salts.
Haage et al. determined the enantiomers of tramadol and
its three main desmethylates in whole blood using an LC-
MS/MS [22]. The chromatographic run time was approxi-
mately 30 min. Ardakani et al. employed a non-particle
Chromolith® high-resolution column and the run time for
LC separation was 7 min [11]. In their method, the mobile
phase consisted of methanol and nonvolatile phosphoric
acid salts solution. Since tramadol is a basic drug with a
pKa of 9.4, a basic mobile phase is better than an acidic
mobile phase in the LC separation. The other methods
also used a mobile phase that included phosphate buffer,
which is not suitable for MS/MS analysis [15, 20]. In con-
trast, the sensitivity in MS/MS detection for tramadol and
its desmethylates declined under basic mobile phase. In
MS/MS detection, two metabolites, ODT and NDT, had
similar molecular masses and fragmentation patterns.
ODT was detectable under the MS/MS condition of
NDT. The retention times of ODT and NDT were 3.4 and
a b
Fig. 3 Plasma concentrations of tramadol, O-desmethylate, N-desmethylate, and N,O-didesmethylate obtained from patients with cancer pain (a)
or non-cancer pain (b) just before treatment of oral tramadol on day 4 or later. (1) Tramadol, (2) O-desmethylate, (3) N-desmethylate, and
(4) N,O-didesmethylate
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7.4 min, respectively, and the present method can
adequately separate these two metabolites. The present
method using an isocratic LC-MS/MS achieves the
simple and rapid determination of tramadol and its
desmethylates.
The precisions and accuracies of the present method
in human plasma for tramadol and its desmethylates
were within 10.9 % and 89.2–106.2 %, respectively.
Tramadol and its desmethylates in plasma specimens
could be stored at room temperature for up to 24 h and
at −80 °C for up to 1 month. Tramadol and its des-
methylates were stable under the pretreatment and
measurement conditions. Many samples can be deter-
mined with the method because the analytes were stable
in injection solutions for up to 24 h after preparation.
More than 500 chromatographic runs were possible with
one ODS column without any deterioration in separ-
ation performance. The results obtained with this
method met the standards of the international US FDA
guideline [19]. This validated method can be utilized to
evaluate the pharmacokinetics of tramadol and its des-
methylates in clinical settings.
The trough plasma concentration ranges of tramadol,
ODT, NDT, and NODT were 18.2–564, 11.8–137, 4.9–
250, and 6.1–147 ng/mL in cancer patients, and 32.8–670,
7.0–84.8, 5.1–317, and 6.7–85.2 ng/mL, respectively, in
non-cancer patients. The calibration curves of tramadol,
ODT, NDT, and NODT in human plasma were linear over
the concentration ranges of 12.5–1600, 2.5–320, 2.5–320,
and 2.5–320 ng/mL, respectively. The plasma concentra-
tion ranges of tramadol and ODT in patients receiving
200 mg of oral tramadol were 100–300 and 40–90 ng/mL,
respectively [23]. The plasma concentration ranges of
tramadol and ODT were measurable within the present
calibration curves. The present method is able to deter-
mine the peak concentrations of tramadol and ODT.
The trough plasma concentrations of tramadol, ODT,
NDT, and NODT in patients with cancer pain or non-
cancer pain showed a large variability in this study. In
addition, their dose-adjusted values and metabolic ratio
to tramadol desmethylates also had a large individual
variation in both populations. Tramadol is a substrate of
CYP2D6, CYP2B6, and CYP3A4 and is rapidly and ex-
tensively metabolized in the liver [24]. In patients with
cancer pain or non-cancer pain, the trough plasma con-
centrations of tramadol, ODT, NDT, and NODT were
not shown for each genotype. Siew et al. demonstrated
that genetic variants of CYP2D6 affected the pharmaco-
kinetics and adverse effects of tramadol [10]. In future
studies, the impact of CYP2D6 genetic variants on the
plasma concentrations of tramadol and its desmethylates
and clinical effects should be evaluated in patients with
cancer pain or non-cancer pain. In addition, some pa-
tients treated with oral tramadol potentially have cancer
cachexia in the present study population. Our previous
reports demonstrated that cancer cachexia decreases the
activity of cytochrome P450 [25, 26]. The difference in
the dose-normalized plasma concentration of tramadol
and its desmethylates between the patients receiving
tramadol oral dispersing tablets and those receiving
tramadol combination tablets were not observed in this
study population (data not shown). Based on our data,
the cancer cachexia may not strongly affect the plasma
exposure of tramadol and its desmethylates in the en-
rolled patients.
The present study has several limitations. First, applica-
tion of the present method is limited to patients receiving
oral tramadol. Oral tramadol undergoes extensive first-pass
metabolism in the liver. In patients treated with intravenous
tramadol, the present method was not verified for suitability
in this report. Second, the present method did not evaluate
the suitability for special populations. Tramadol is elimi-
nated by hepatic metabolism and renal excretion. The
present method needs to be verified in patients with severe
renal impairment or hepatic dysfunction. Third, this study
did not characterize the difference in the plasma exposure
of tramadol and its desmethylates between the patients
with cancer pain and those with non-cancer pain. The
pharmacokinetics may be affected by the pathology, meals,
and concomitant drugs. Future clinical studies should as-
sess interindividual variation in tramadol pharmacokinetics
in patients treated with oral tramadol. Forth, this method
determined the total concentration of tramadol and its des-
methylates in human plasma. Although the plasma protein
binding of tramadol is approximately 20 % [27], no infor-
mation on the protein binding of the desmethylates is ob-
tained. Analytical method that determines the free
tramadol and its desmethylates would reveal the interindi-
vidual variation in tramadol pharmacokinetics.
Conclusions
A simultaneous and isocratic LC-MS/MS method for
the determination of tramadol and its desmethylates in
human plasma has been established. This method pos-
sesses an acceptable degree of precision and accuracy in
accordance with international guidelines [19]. This ana-
lytical method can be helpful for evaluating the pharma-
cokinetics of oral tramadol, including the determination
of its desmethylates, in patients with cancer pain or
non-cancer pain.
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